AnalysisTexas abortion pill ruling could disrupt US drug oversight

WASHINGTON (Reuters) – A federal judge in Texas could soon order the U.S. Food and Drug Administration to withdraw its approval of abortion pill mifepristone, a move that if allowed to stand could severely undermine the agency, health policy and legal experts said. The closely followed case could potentially lead to a nationwide ban on mifepristone – part of a two-drug regimen that accounts for more than half of U.S. abortions – and call into question the FDA’s power to regulate all drugs nationwide, they said. It also risks leading to self-censure by the pharmaceutical industry as drugmakers embrace treatments…